

*E' cord.* 40. (Amended) The polypeptide of claims [13] 23, 24, 29, 36 and 37 further comprising Met at the amino terminus.

---

Please add the following new claims:

-- 41. The polypeptide of claim 29, which shows preferential mitogenic activity for BALB/MK epithelial cells, but not NIH/3T3 cells.

*E<sup>2</sup>* 42. A KGF or KGF-like protein, according to claim 13, which is glycosylated.

*G* 43. A pharmaceutical composition comprising the polypeptide or portion thereof of any one of claims 40-42 and a pharmaceutically acceptable carrier.--

---

REMARKS

Claims 13, 14, 21, 23, 24, 29, and 33-40 are pending in this application. Applicants herewith amend claims 39 and 40, cancel claims 21, 31, 32, 33, 34, 35 and 38, without prejudice or disclaimer, and add new claims 41-43. Thus, with the entry of this amendment, claims 13, 14, 23, 24, 29, 36, 37, 39, 40, 41, 42 and 43 will be active in this case.

The purpose of this amendment is to obviate certain double-patenting rejections in co-pending U.S. Patent Application Serial No. 08/477,983.

Serial No. 08/477,983

CONCLUSION

Applicants respectfully assert that claims 13, 14, 23, 24, 29, 36, 37, 39, 40, 41, 42 and 43 meet all of the statutory requirements of patentability and therefore are in condition for allowance. Examiner Saoud is invited to contact the undersigned for any matter in furtherance of the prosecution of this case.

Respectfully submitted,

May 23, 1997  
Date

Patricia D. Granados  
Patricia D. Granados  
Reg. No. 33,683

FOLEY & LARDNER  
Suite 500  
3000 K Street, N.W.  
Washington, DC 20007-5109  
(202) 672-5477

RECEIVED

MAY 23 1997

MATRIX CUSTOMER  
SERVICE CENTER